Tuesday, April 19, 2016

BRIEF-RXI Pharmaceuticals says received notice of allowance for RXI-109 from USPTO

* RXI Pharmaceuticals says fortifies its novel RNAi patent

portfolio with notice of allowance for lead clinical candidate

RXI-109

Source text for Eikon:

Further company coverage:

(Bengaluru Newsroom: +1 646 223 8780)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)